Flexential Boosts Audience Engagement with ON24 AI Capabilities

Krista Davis, Senior Vice President and Chief Human Resources Officer at ANI Pharmaceuticals Inc (ANIP), sold 1,763 shares of the company on August 22, 2025. Following this transaction, Davis owns 62,896 shares of ANI Pharmaceuticals Inc. This is the 36th insider sell over the past year, with a total of 6,629 shares sold and 0 shares purchased. Shares of ANI Pharmaceuticals Inc were trading for $91.1 apiece on the day of the sale, giving the stock a market cap of $1,958.931 million and a price-to-GF-Value ratio of 1.09, indicating a Fairly Valued stock based on its GF Value.

ANI Pharmaceuticals Inc. (ANIP) has seen significant insider selling activity recently, with Senior Vice President and Chief Human Resources Officer Krista Davis selling 1,763 shares of the company on August 22, 2025. This transaction occurred at a price of $91.1 per share, resulting in a total sale of $160,609. Following this sale, Davis directly owns 62,896 shares of ANIP [2].

This sale is the 36th insider sell over the past year, with a total of 6,629 shares sold and 0 shares purchased. The stock was trading at $91.1 on the day of the sale, giving it a market cap of $1,958.931 million and a price-to-GF-Value ratio of 1.09, indicating a fairly valued stock based on its GF Value [3].

ANIP has been performing well, with the stock up 36.5% over the past month and hitting a new 52-week high of $91.54 in the previous session. The company has also gained 64.9% since the start of the year compared to the -2.4% move for the Zacks Medical sector and the 4.1% return for the Zacks Medical - Biomedical and Genetics industry [3].

The company's strong earnings record, with no misses in the last four quarters, has contributed to its positive performance. In its last earnings report on August 8, 2025, ANIP reported EPS of $1.8 versus the consensus estimate of $1.38, while it beat the consensus revenue estimate by 12.22% [3].

For the current fiscal year, ANIP is expected to post earnings of $7.25 per share on $840.7 in revenues, representing a 39.42% change in EPS and a 36.84% change in revenues. For the next fiscal year, the company is expected to earn $7.74 per share on $904.39 in revenues, representing a year-over-year change of 6.64% and 7.58%, respectively [3].

Valuation metrics indicate that ANIP is fairly valued, with a Value Score of B, Growth Score of A, and Momentum Score of A, giving it a VGM Score of A. The stock currently trades at 12.6X current fiscal year EPS estimates and 12X on a trailing cash flow basis, which is not in line with the peer industry average of 20.1X and 16.1X, respectively [3].

ANIP's Zacks Rank of #1 (Strong Buy) further supports its investment potential. The stock meets the requirements for a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, indicating that there could be more room for the stock to run in the near term [3].

References:
[1] https://www.stocktitan.net/sec-filings/ANIP/form-4-ani-pharmaceuticals-inc-insider-trading-activity-f33af17be96b.html
[2] https://www.tradingview.com/news/tradingview:f41eb6169aa95:0-ani-pharmaceuticals-executive-sells-shares/
[3] https://www.nasdaq.com/articles/ani-pharmaceuticals-inc-anip-hits-fresh-high-there-still-room-run
[4] https://ca.finance.yahoo.com/quote/ANIP/